文献速递瓣膜病与结构性心脏病

PARTNER 3试验:低外科风险重度主动脉瓣狭窄患者TAVR与SAVR的经济学结局

Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial.
PubMed 文献 · Circulation · 2023-05-08

基于PARTNER 3试验中929例美国低外科风险重度主动脉瓣狭窄患者,比较经股动脉TAVR(SAPIEN 3瓣膜)与SAVR的终身成本效果。

要点

  • 低外科风险患者中,TAVR相比SAVR 2年成本节省2030美元/患者。
  • 若SAVR有适度长期生存优势,则SAVR更具成本效果。

核心结论

  • 在类似PARTNER 3试验的低外科风险重度主动脉瓣狭窄患者中,经股动脉TAVR使用SAPIEN 3瓣膜相比SAVR在2年时成本节省,且只要两种策略晚期死亡无实质差异,长期具有经济吸引力。

研究设计与样本

  • PARTNER 3试验经济学子研究,纳入929例美国低外科风险重度主动脉瓣狭窄并接受瓣膜置换的患者,随机分配至TAVR或SAVR。
  • 采用Markov模型基于试验内数据估计终身成本效果,视角为美国医疗系统。

主要发现

  • TAVR随访成本更低,导致2年成本节省2030美元/患者(95%CI,-6222至1816美元)。
  • TAVR获得0.05质量调整生命年(95%CI,-0.003至0.102)。

关键数值与推荐

  • 若SAVR具有适度长期生存优势,则SAVR相比TAVR具有成本效果(但非成本节省)。

临床怎么用

  • 对于低外科风险重度主动脉瓣狭窄患者,TAVR在2年时成本节省且长期经济价值高,但需关注长期生存差异以最终确定首选策略。

局限性

  • 结果对长期生存差异敏感,长期随访对确定临床和经济首选策略至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with severe symptomatic aortic stenosis at low surgical risk, transfemoral transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve has been shown to reduce the composite of death, stroke, or rehospitalization at 2-year follow-up compared with surgical aortic valve replacement (SAVR). Whether TAVR is cost-effective compared with SAVR for low-risk patients remains uncertain. METHODS: Between 2016 and 2017, 1000 low-risk patients with aortic stenosis were randomly assigned to TAVR with the SAPIEN 3 valve or SAVR in the PARTNER 3 trial (Placement of Aortic Transcatheter Valves). Of these patients, 929 underwent valve replacement, were enrolled in the United States, and were included in the economic substudy. Procedural costs were estimated using measured resource use. Other costs were determined by linkage with Medicare claims or by regression models when linkage was not feasible. Health utilities were estimated using the EuroQOL 5-item questionnaire. With the use of a Markov model informed by in-trial data, lifetime cost-effectiveness from the perspective of the US health care system was estimated in terms of cost per quality-adjusted life-year gained. RESULTS: Although procedural costs were nearly $19 000 higher with TAVR, total index hospitalization costs were only $591 more with TAVR compared with SAVR. Follow-up costs were lower with TAVR such that TAVR led to 2-year cost savings of $2030/patient compared with SAVR (95% CI, -$6222 to $1816) and a gain of 0.05 quality-adjusted life-years (95% CI, -0.003 to 0.102). In our base-case analysis, TAVR was projected to be an economically dominant strategy with a 95% probability that the incremental cost-effectiveness ratio for TAVR would be <$50 000/quality-adjusted life-year gained (consistent with high economic value from a US health care perspective). These findings were sensitive to differences in long-term survival, however, such that a modest long-term survival advantage with SAVR would render SAVR cost-effective (although not cost saving) compared with TAVR. CONCLUSIONS: For patients with severe aortic stenosis and low surgical risk similar to those enrolled in the PARTNER 3 trial, transfemoral TAVR with the SAPIEN 3 valve is cost saving compared with SAVR at 2 years and is projected to be economically attractive in the long run as long as there are no substantial differences in late death between the 2 strategies. Long-term follow-up will be critical to ultimately determine the preferred treatment strategy for low-risk patients from both a clinical and economic perspective.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Galper BZ, Chinnakondepalli KM, Wang K, et al. Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial. Circulation. 2023. PMID: 37154049. doi:10.1161/CIRCULATIONAHA.122.062481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。